Suicide Gene Therapy

Combination Vector Strategy Attacks Pancreatic Cancer

Published in Gene Therapy Weekly, May 24th, 1999

Enhanced killing of pancreatic tumors in vivo was realized when adenovirus and retrovirus vectors where combined in a herpes simplex virus thymidine kinase/ganciclovir (HSVtk/GCV) suicide gene therapy approach.

Suicide gene therapy may provide hope for future pancreatic cancer patients who face a dismal prognosis. Historically, two types of vectors have undergone intense scrutiny in the lab for potential suicide gene therapy approaches. These are adenovirus- and retrovirus-based vectors. Both vectors have their attributes and drawbacks.

M. Carrio and colleagues from the Universitat de Barcelona and the Institut de Recerca Oncologica, Spain,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1999-05-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry